ELI LILLY AND COMPANY Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31)
ELI LILLY AND COMPANY (LLY) had Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) of $0 as of 2013-12-31, per its 10-K filed 2014-02-19.
Discontinued › Notes › Debt › Line of Credit Facility
us-gaap:LineOfCreditFacilityAmountOutstanding · last filed 2014-02-19
- 2013-12-31: Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) $0.00.
- 2012-12-31: Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) $0.00.
| Period end | Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) |
|---|---|
| 2013-12-31 | $0.00 10-K · filed 2014-02-19 |
| 2012-12-31 | $0.00 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |